Open Access Green as soon as Postprint is submitted to ZB.
Assessment of small fiber neuropathy to predict future risk of type 2 diabetes.
Prim. Care Diabetes 7, 269-273 (2013)
OBJECTIVE: Sudomotor dysfunction due to small fiber neuropathy can be observed very early in pre-diabetes. The aim of this study was to assess the predictive power of EZSCAN, a non invasive, quick and simple measurement of sudomotor function to identify glucose impairment. RESEARCH DESIGN AND METHODS: The study was performed in 76 German subjects at risk of diabetes. Glucose metabolism was assessed by using, oral glucose tolerance test (OGTT) at baseline and after 2 year follow-up. Sudomotor function was evaluated by measuring hand and foot electrochemical sweat conductances to calculate a risk score. RESULTS: At baseline, 38 patients had normal glucose tolerance (NGT), 34 had pre-diabetes (impaired fasting glucose, IFG and/or impaired glucose tolerance, IGT) and 4 had newly diagnosed type 2 diabetes. The AUC values for FPG, 2h-OGTT glucose, 1h-OGTT glucose, HbA1C and EZSCAN score to predict pre-diabetes were 0.50, 0.65, 0.64, 0.72 and 0.76, respectively. Subjects having a moderate or high EZSCAN score (>50) at baseline had a substantially increased risk for having IFG and/or IGT at follow-up visit presented by an odds ratio of 12.0 [1.4-100.5], the OR for having 1h-OGTT ≥ 8.6mmol/L at follow-up was 9.8 [1.0-92.8] and for having HbA1C ≥ 5.7% was 15.7 [1.9-131.5] compared to subjects with low EZSCAN risk. CONCLUSIONS: This preliminary study, which must be confirmed in a larger population, shows that EZSCAN risk score is associated with diabetes progression which have implications for prevention and disease management.
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Diabetes Progression ; Diabetes Risk ; Prediction Of Type 2 Diabetes ; Small Fiber Neuropathy
ISSN (print) / ISBN 1878-0210
Journal Primary Care Diabetes
Quellenangaben Volume: 7, Issue: 4, Pages: 269-273
Publishing Place Amsterdam [u.a.]
Reviewing status Peer reviewed
Institute(s) Institute for Pancreatic Beta Cell Research (IPI)